Voyager Therapeutics (VYGR) AI Stock Analysis

• Market Cap: $195.89M
• Dividend Yield: N/A
• Average Volume (3M): 553.29K
• Price to Earnings (P/E): 5.0
• Beta (1Y): 1.37
• Revenue Growth: -43.75%
• EPS Growth: -8479.41%
• Country: US
• Employees: 172
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.53
• Shares Outstanding: 55,336,445
• 10 Day Avg. Volume: 972,527
• 30 Day Avg. Volume: 553,290
• PEG Ratio: 0.08
• Price to Book (P/B): 0.72
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.63
• Enterprise Value/Market Cap: 0.78
• Enterprise Value/Revenue: 0.34
• Enterprise Value/Gross Profit: 4.70
• Enterprise Value/Ebitda: -0.93
• 1Y Price Target: $15.00
• Price Target Upside: 347.76% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10

• Rating: 46 Neutral
• Price Target: $3.50 ▲(4.48%Upside)

Voyager Therapeutics' overall stock score is primarily influenced by its financial performance, which is strained due to negative profitability and cash flow issues. Technical analysis provides some short-term positive signals, but the valuation remains challenging due to negative earnings and no dividend yield.

Positive Factors

Cash Reserves

Voyager has $295M in cash and a projected runway into mid-2027, indicating meaningful potential value creation from clinical advancement, partnering activity, and platform validation.

Partnership Milestones

Voyager could realize up to $35mm in regulatory and clinical milestones related to the FXN/GBA1 programs.

Pipeline Progress

Voyager reported continued progress across its tau-targeting Alzheimer’s programs and partnered gene therapy pipeline, with key milestones expected over the next 12–18 months.

Negative Factors

Financial Performance

Net loss per share was ($0.53) vs consensus of ($0.45).

Stock Performance

The stock has pulled back approximately 43% this year due to macro factors and investor apathy around small/mid-cap biotech.

Stock Price Target

The price target has been reduced from $13 to $12.

Voyager Therapeutics Business Overview & Revenue Model

Company Description

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Voyager Therapeutics generates revenue primarily through strategic collaborations and licensing agreements with larger pharmaceutical companies, where it provides access to its AAV technology platform and intellectual property in exchange for upfront payments, milestone payments, and royalties on future product sales. Additionally, the company may receive government grants and research funding to support its development programs. These partnerships and funding arrangements are critical to sustaining its research and development activities.

Voyager Therapeutics Financial Statement Overview

Summary

Voyager Therapeutics faces significant financial challenges, including revenue volatility, negative profit margins, and strained cash flow. Despite a stable equity position and manageable leverage, the company's profitability and cash flow sustainability are major concerns.

Income Statement

Voyager Therapeutics has experienced significant revenue volatility, with recent declines from previous highs, reflecting potential challenges in maintaining consistent revenue streams. The TTM Gross Profit Margin is 48.54%, indicating some efficiency in managing production costs, but the Net Profit Margin is negative, highlighting ongoing profitability challenges. The EBIT and EBITDA Margins are also negative, reinforcing the company's struggles to achieve operational profitability.

Balance Sheet

The company's balance sheet shows a relatively stable equity position with a Debt-to-Equity Ratio of 0.15, suggesting manageable leverage levels. The Equity Ratio is robust, at 77.20%, indicating strong equity financing. However, Return on Equity is negative due to persistent net losses, which is a concern for investors seeking returns.

Cash Flow

The company's cash flow situation is strained, with negative Free Cash Flow growth, indicating challenges in generating cash from operations. The Operating Cash Flow to Net Income Ratio is negative, reflecting difficulties in converting income into cash flow. Despite these challenges, there was a significant cash inflow from financing activities in the prior period, which temporarily bolstered liquidity.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
66.96M	80.00M	250.01M	40.91M	37.41M	171.13M
	Gross Profit
32.51M	80.00M	245.57M	34.72M	-36.37M	62.38M
	EBIT
-101.80M	-83.29M	122.01M	-50.84M	-73.62M	27.38M
	EBITDA
-97.25M	-78.56M	126.45M	-44.65M	-68.45M	31.20M
	Net Income Common Stockholders
-84.69M	-65.00M	132.33M	-46.41M	-66.03M	36.74M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
161.51M	266.68M	230.88M	118.85M	132.54M	181.14M
	Total Assets
237.72M	393.05M	351.28M	159.36M	193.85M	261.58M
	Total Debt
47.74M	43.73M	20.29M	23.13M	44.18M	47.61M
	Net Debt
-70.06M	-27.64M	-48.51M	-75.83M	-73.25M	-56.83M
	Total Liabilities
101.51M	93.29M	114.96M	100.34M	98.80M	107.26M
	Stockholders Equity
136.21M	299.76M	236.32M	59.02M	95.06M	154.32M
Cash Flow		Free Cash Flow
-114.01M	-18.83M	74.66M	-15.00M	-55.13M	-108.81M
	Operating Cash Flow
-111.97M	-15.31M	77.92M	-12.51M	-53.52M	-96.72M
	Investing Cash Flow
42.41M	-94.86M	-141.64M	-7.34M	65.91M	113.00M
	Financing Cash Flow
1.24M	114.02M	33.65M	1.11M	612.00K	3.16M

Voyager Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.35
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VYGR, the sentiment is Neutral. The current price of 3.35 is above the 20-day moving average (MA) of 3.17, above the 50-day MA of 3.26, and below the 200-day MA of 5.13, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 53.27 is Neutral, neither overbought nor oversold. The STOCH value of 69.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for VYGR.

Voyager Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FHTX	54 Neutral	$248.61M	―	322.49%	―	-30.66%	36.48%
Sector *	54 Neutral	$5.31B	3.26	-45.10%	2.79%	16.76%	0.02%
FDMT	48 Neutral	$201.51M	―	-32.97%	―	―	―
VYGR	46 Neutral	$195.89M	5.05	-27.61%	―	-43.75%	-8479.41%
TERN	45 Neutral	$323.15M	―	-32.12%	―	―	10.98%
PRME	43 Neutral	$221.89M	―	-115.21%	―	―	20.58%
ANNX	38 Underperform	$285.26M	―	-66.13%	―	―	43.21%

Voyager Therapeutics Corporate Events

Voyager Therapeutics Approves Stock Plans at Annual Meeting

At the annual meeting held on June 3, 2025, Voyager Therapeutics‘ stockholders approved the 2025 Stock Incentive Plan and the Amended and Restated 2015 Employee Stock Purchase Plan, both previously adopted by the Board of Directors. Additionally, stockholders elected four Class I directors to serve until the 2028 meeting, approved executive compensation, and ratified Ernst & Young LLP as the independent accounting firm for the fiscal year ending December 31, 2025. These decisions are expected to impact the company’s governance and operational strategies moving forward.

The most recent analyst rating on (VYGR) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Voyager Therapeutics stock, see the VYGR Stock Forecast page.